| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BB2; CD54; Cell surface glycoprotein P3.58; Human rhinovirus receptor; ICAM1; intercellular adhesion molecule 1 (CD54); Intercellular adhesion molecule 1; Major group rhinovirus receptor; MALA2; MyD10; P3.58; Surface antigen of activated B cells;ICAM 1 |
| WB Predicted band size | Calculated MW: 58 kDa ; Observed MW: 80-110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | A synthesized peptide derived from mouse ICAM 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于ICAM1/CD54抗体的参考文献及其摘要概括：
---
1. **"ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α-activated vascular endothelium under flow"**
*作者：Yang L, Froio RM, Sciuto TE, et al.*
摘要：该研究利用抗ICAM-1抗体阻断实验，揭示了ICAM-1在炎症条件下介导中性粒细胞与血管内皮细胞黏附及跨细胞迁移的关键作用，为靶向ICAM-1的抗炎治疗提供了依据。
---
2. **"Anti-ICAM-1 antibody-mediated cytoprotection of endothelial cells from neutrophil-induced injury"**
*作者：Smith CW, Rothlein R, Hughes BJ, et al.*
摘要：通过使用抗ICAM-1抗体抑制中性粒细胞与内皮细胞的相互作用，证明阻断ICAM-1可显著减少炎症反应导致的内皮细胞损伤，提示其在减轻组织炎症中的潜在应用。
---
3. **"ICAM-1-targeted antibody-drug conjugate exhibits potent antitumor activity in preclinical models"**
*作者：Wang Q, Chen Y, Park J, et al.*
摘要：研究开发了一种靶向ICAM-1的抗体-药物偶联物(ADC)，并证明其在多种肿瘤模型中通过抗体介导的靶向递送显著抑制肿瘤生长，为ICAM-1抗体在癌症治疗中的应用提供了新策略。
---
如需更具体的文献或领域(如感染、自身免疫病等)，可进一步补充说明。
ICAM-1 (Intercellular Adhesion Molecule 1), also known as CD54. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It plays a critical role in mediating leukocyte adhesion and trafficking during inflammatory responses. Expressed on endothelial cells, immune cells, and other cell types, ICAM-1 interacts with integrins like LFA-1 (lymphocyte function-associated antigen 1) to facilitate immune cell recruitment to sites of infection, injury, or immune activation. Its expression is upregulated by pro-inflammatory cytokines (e.g., TNF-α, IL-1) or microbial stimuli, making it a key biomarker in inflammatory and autoimmune diseases, atherosclerosis, and cancer metastasis.
ICAM1/CD54 antibodies are tools used to detect or modulate ICAM-1 activity in research and therapeutic contexts. As detection reagents, they enable visualization of ICAM-1 expression in tissues (e.g., via immunohistochemistry) or quantification in soluble form (sICAM-1) in bodily fluids, aiding disease monitoring. Functionally, blocking antibodies inhibit ICAM-1/LFA-1 interactions, suppressing leukocyte adhesion in preclinical models of inflammation, transplant rejection, or autoimmune disorders. While therapeutic applications remain largely experimental, some antibody-based strategies have entered clinical trials for conditions like acute lung injury. These antibodies are also vital in studying ICAM-1's roles in viral entry (e.g., rhinoviruses) and tumor microenvironment modulation. Cross-reactivity with ICAM-1 orthologs in mice, rats, or primates supports translational research.
×
